{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T10:42:53Z","timestamp":1701686573458},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1007\/s00393-023-01449-9","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T14:02:21Z","timestamp":1699624941000},"page":"882-884","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Umgang mit NSAR bei der Behandlung der axialen Spondyloarthritis","Dealing with NSAID in the treatment of axial spondylarthritis"],"prefix":"10.1007","volume":"82","author":[{"given":"Denis","family":"Poddubnyy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"issue":"1","key":"1449_CR1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro\u00a0S, Nikiphorou\u00a0E, Sepriano\u00a0A, Ortolan\u00a0A, Webers\u00a0C, Baraliakos\u00a0X et al (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19\u201334","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"1449_CR2","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1002\/art.39690","volume":"68","author":"D Poddubnyy","year":"2016","unstructured":"Poddubnyy\u00a0D, Listing\u00a0J, Brief Report\u00a0SJ (2016) Course of active inflammatory and fatty lesions in patients with early axial spondyloarthritis treated with Infliximab plus Naproxen as compared to Naproxen alone: results from the Infliximab as first line therapy in patients with early active axial Spondyloarthritis trial. Arthritis Rheumatol 68(8):1899\u20131903","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"1449_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s11926-017-0681-5","volume":"19","author":"D Poddubnyy","year":"2017","unstructured":"Poddubnyy\u00a0D, Sieper\u00a0J (2017) Mechanism of new bone formation in axial spondyloarthritis. Curr Rheumatol Rep 19(9):55","journal-title":"Curr Rheumatol Rep"},{"issue":"9","key":"1449_CR4","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s00393-019-0650-7","volume":"78","author":"H Haibel","year":"2019","unstructured":"Haibel\u00a0H, Redeker\u00a0I, Zink\u00a0A, Callhoff\u00a0J, Marschall\u00a0U, Hoffmann\u00a0F et\u00a0al (2019) Health care and disease burden in persons with axial spondyloarthritis in Germany. Z\u00a0Rheumatol 78(9):865\u2013874","journal-title":"Z Rheumatol"},{"issue":"11","key":"1449_CR5","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1136\/ard.2011.151191","volume":"70","author":"G Bakland","year":"2011","unstructured":"Bakland\u00a0G, Gran\u00a0JT, Nossent\u00a0JC (2011) Increased mortality in ankylosing spondylitis is related to disease activity. Ann Rheum Dis 70(11):1921\u20131925","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1449_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7326\/M14-2470","volume":"163","author":"NN Haroon","year":"2015","unstructured":"Haroon\u00a0NN, Paterson\u00a0JM, Li\u00a0P, Inman\u00a0RD, Haroon\u00a0N (2015) Patients with Ankylosing Spondylitis have increased cardiovascular and cerebrovascular mortality: a\u00a0population-based study. Ann Intern Med 163(6):409\u2013416","journal-title":"Ann Intern Med"},{"issue":"2","key":"1449_CR7","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1136\/ard.2010.133488","volume":"70","author":"M Dougados","year":"2011","unstructured":"Dougados\u00a0M, Simon\u00a0P, Braun\u00a0J, Burgos-Vargas\u00a0R, Maksymowych\u00a0WP, Sieper\u00a0J, van der Heijde\u00a0D (2011) ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis. Ann Rheum Dis 70(2):249\u2013251","journal-title":"Ann Rheum Dis"},{"key":"1449_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010952.pub2","author":"FP Kroon","year":"2015","unstructured":"Kroon\u00a0FP, van der Burg\u00a0LR, Ramiro\u00a0S, Landewe\u00a0RB, Buchbinder\u00a0R, Falzon\u00a0L, van der Heijde\u00a0D (2015) Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD010952.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"1449_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207677","author":"R Wang","year":"2015","unstructured":"Wang\u00a0R, Dasgupta\u00a0A, Ward\u00a0MM (2015) Comparative efficacy of non-steroidal anti-inflammatory drugs in ankylosing spondylitis: a\u00a0Bayesian network meta-analysis of clinical trials. Ann Rheum Dis. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207677","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1449_CR10","first-page":"3031","volume":"19","author":"M Fan","year":"2020","unstructured":"Fan\u00a0M, Liu\u00a0J, Zhao\u00a0B, Wu\u00a0X, Li\u00a0X, Gu\u00a0J (2020) Indirect comparison of NSAIDs for ankylosing spondylitis: network meta-analysis of randomized, double-blinded, controlled trials. Exp Ther Med 19(4):3031\u20133041","journal-title":"Exp Ther Med"},{"issue":"1","key":"1449_CR11","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1186\/s12891-016-1275-5","volume":"17","author":"E Balazcs","year":"2016","unstructured":"Balazcs\u00a0E, Sieper\u00a0J, Bickham\u00a0K, Mehta\u00a0A, Frontera\u00a0N, Stryszak\u00a0P et\u00a0al (2016) A\u00a0randomized, clinical trial to assess the relative efficacy and tolerability of two doses of etoricoxib versus naproxen in patients with ankylosing spondylitis. BMC Musculoskelet Disord 17(1):426","journal-title":"BMC Musculoskelet Disord"},{"issue":"4","key":"1449_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.23275","volume":"58","author":"IH Song","year":"2008","unstructured":"Song\u00a0IH, Poddubnyy\u00a0DA, Rudwaleit\u00a0M, Sieper\u00a0J (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929\u2013938","journal-title":"Arthritis Rheum"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01449-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-023-01449-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-023-01449-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,4]],"date-time":"2023-12-04T10:04:00Z","timestamp":1701684240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-023-01449-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["1449"],"URL":"https:\/\/doi.org\/10.1007\/s00393-023-01449-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"11 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"D.\u00a0Poddubnyy gibt folgende potenzielle Interessenkonflikte an: Forschungsf\u00f6rderung durch: AbbVie, Eli Lilly, MSD, Novartis, Pfizer; Beratert\u00e4tigkeit f\u00fcr: AbbVie, Bristol-Myers Squibb, Biocad, Eli Lilly, Janssen, MoonLake, Novartis, Pfizer, and UCB; Referentent\u00e4tigkeit f\u00fcr: AbbVie, Canon, DKSH, Eli Lilly, Janssen, MSD, Medscape, Novartis, PeerVoice, Pfizer und UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden vom Autor keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}